Enhanced therapeutic efficacy of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice

Anti-Cancer Drugs

Volumn 15, Issue 8, 2004, Pages 773-778

  Lei, Sabrina ^a   Chien, Pei Yu ^a   Sheikh, Saifuddin ^a   Zhang, Allen ^a   Ali, Shahid ^a   Ahmad, Imran ^a  

^a NeoPharm Inc   (United States)

Author keywords

CPT 11; Cytotoxicity; Human tumor xenografts; Liposome based formulation; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; IRINOTECAN; LIPOSOME; PRODRUG; SOLVENT; SULFORHODAMINE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER REGRESSION; COLON CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; SCID MOUSE; TUMOR MODEL; TUMOR XENOGRAFT;

ANIMALS; BIOMEDICAL ENHANCEMENT; CAMPTOTHECIN; CELL LINE, TUMOR; CLINICAL TRIALS, PHASE I; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; HT29 CELLS; HUMANS; INJECTIONS, INTRAVENOUS; LIPOSOMES; MICE; MICE, SCID; TECHNOLOGY, PHARMACEUTICAL; TRANSPLANTATION, HETEROLOGOUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 4644310318     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200409000-00006     Document Type: Article

References (27)

1. Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993; 11:909-913.
2. Cardenal F, Domine M, Massuti B, et al. Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study. Lung Cancer 2003; 39:201-207.
3. Taguchi T, Tominaga T, Ogawa M, Ishida T, Morimoto K, Ogawa N. A late phase II study of CPT-11 (irinotecan) in advanced breast cancer. Gan To Kagaku Ryoho 1994; 21:1017-1024.
4. Bodurka DC, Levenback C, Wolf JK, et al. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol 2003; 21:291-297.
5. Hsiang YH, Hertzberg R, Hecht S, Lui LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260:14873-14878.
6. Hsiang YH, Lihou MG, Lui LF. Arrest of DNA replication by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by Camptothecin. Cancer Res 1989; 49:5077-5082.
7. Holm C, Covey JM, Kerrigan D, Pommier Y. Differential requirement of DNA replication for the cytotoxicity of DNA-topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res 1989; 49:6365-6368.
8. Slatter JG, Su P, Sams JP, Schaaf LJ, Wienkers LC. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Disp 1997; 25:1157-1164.
9. 14C]CPT-11 in cancer patients. Drug Metab Disp 2000; 28:423-433.
10. Gokhale PC, Pei J, Zhang C, Ahmad I, Rahman A, Kasid U. Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone. Anticancer Res 2001; 21:3313-3321.
11. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 1988; 85:6949-6953.
12. Waterhouse DN, Tardi PG, Mayer LD, Bally MB. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf 2001; 24:903-920.
13. Zhang JA, Xuan T, Parmar M, Ma L, Ugwu S, Ali S, Ahmad I. Development and characterization of a novel liposome-based formulation of SN-38. Int J Pharm 2004; 270:93-107.
14. Khan S, Ahmad A, Guo W, Wang Y-F, Abu-Qare A, Ahmad I. A simple and sensitive LC/MS/MS assay for 7-ethyl-10-hydroxycamptothecin (SN-38) in mouse plasma and tissues:application to pharmacokinetic study of liposome entrapped SN-38 (LE-SN38). J Pharmac Biomed Anal 2004; in press.
15. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-1112.
16. Dancey J, Eisenhauer EA. Current perspectives on camptothecins in cancer treatment. Br J Cancer 1996; 74:327-328.
17. Cersosimo RJ. Irinotecan: a new antineoplastic agent for the management of colorectal cancer. Ann Pharmacother 1998; 32:1324-1333.
18. Sadzuka Y. Effective prodrug liposome and conversion to active metabolite. Curr Drug Metab 2000; 1:31-48.
19. Takayanagi I, Koike K, Tagawa M, Mitsuhashi E. Some pharmacological properties of a new antitumor drug, CPT-11, in isolated muscle preparations. Gen Pharmacol 1989; 20:763-776.
20. Guichard S, Terret C, Hennebelle I, et al. CPT-11 converting carboxylesterase and topoisomerase I activities in tumor and normal colon and liver tissues. Br J Cancer 1999; 80:364-370.
21. Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 2000; 60:1189-1192.
22. Ohtsuka K, Kameyama M, Kanetoshi A, Fujimoto T, Takaoka K, Shida AY. Intracellular conversion of irinotecan to its active form, SN-38, by native carboxylesterase in human non-small cell lung cancer. Lung Cancer 2003; 41:187-188.
23. Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001; 7: 2182-2194.
24. Pavillard V, Agostini C, Richard S, Charasson V, Montaudon D, Robert J. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother Pharmacol 2002; 49:329-335.
25. Van Hattum AH, Pinedo HM, Schluper HM, Hausheer FH, Boven E. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Int J Cancer 2000; 88:260-266.
26. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991; 51:4187-4191.
27. Jansen WJ, Zwart B, Hulscher ST, Giaccone G, Pinedo HM, Boven E. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Int J Cancer 1997; 70:335-340.